Cardiovascular Disease

sec_arr References

References for Hypertension and Coronary Artery Disease (CAD)

  1. Varvarigou V, Farioli A, Korre M, Sato S, Dahabreh IJ, Kales SN. Law enforcement duties and sudden cardiac death among police officers in United States: case distribution study. BMJ. 2014;349:1-9. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240529/. Accessed July 3, 2018.
  2. Zimmerman F. Cardiovascular disease and risk factors in law enforcement personnel: a comprehensive review. Card Review. 2012;20:159-66.
  3. Joint National Committee. The sixth report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157(21):2413-46.
  4. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;5:142-61.
  5. Black HR, Sica D, Ferdinand K, White WB; on behalf of the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and the American College of Cardiology. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 6: hypertension: a scientific statement from the American Heart Association and the American College of Cardiology. 2015;132:e298-e302. Available at: http://circ.ahajournals.org/content/132/22/e298.full. Accessed July 3, 2018.
  6. S. Preventive Services Task Force. Final Recommendation Statement: High Blood Pressure in Adults: Screening. November 2016. Available at: https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/high-blood-pressure-in-adults-screening. Accessed July 3, 2018.
  7. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52. Available at: http://hyper.ahajournals.org/cgi/content/full/42/6/1206. Accessed July 3, 2018.
  8. Schmieder RE: End organ damage in hypertension. Dtsch Arztebl Int. 2010;107(49):866-73.
  9. Inker LA, Astor BC, Fox CH, et al. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. Am J Kidney Dis. 2014;63(5):713-35. Available at: http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf. Accessed July 3, 2018.
  10. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Part 7. Stratification of risk for progression of kidney disease and development of cardiovascular disease; Guideline 15. Association of chronic kidney disease with cardiovascular disease. 2002. Available at: https://www.kidney.org/sites/default/files/docs/ckd_evaluation_classification_stratification.pdf. Accessed July 3, 2018.
  11. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. 2010;375:2073-81.
  12. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. 2001;286:421-6.
  13. Hallan S, Astor B, Romundstad S, et al. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: the HUNT II Study. Arch Intern Med. 2007;167:2490-6.
  14. Ibsen H, Wachtell K, Olsen MH et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Kidney Int Suppl. 2004;92:S56-8.
  15. Joint British Societies. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. 2005;91(Suppl 5):v1-52.
  16. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
  17. Wong TY, Mitchell. Hypertensive retinopathy. N Eng J Med. 2004;351(22):2310-7.
  18. D’Agostino RB, Russell HM, Juse DM, et al. 2000. Primary and subsequent coronary risk appraisal: new results from the Framingham Study. Am Heart J. 2000;139:272-81.
  19. American College of Cardiology, American Heart Association. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol. 2014;63(25):2935‐ Available at: http://www.cvriskcalculator.com. Accessed July 3, 2018.
  20. Blumenthal RS, Epstein AE, Kerber RE. Expert Panel Recommendations Cardiovascular Disease and Commercial Motor Vehicle Driver Safety. US Department of Transportation, Federal Motor Carrier Safety Administration. April 10, 2007. Available at: https://www.fmcsa.dot.gov/sites/fmcsa.dot.gov/files/docs/Cardiovascular_Disease.pdf. Accessed July 3, 2018.
  21. California Commission on Peace Officer Standards and Training (POST). Medical Screening Manual for California Law Cardiovascular System. 2014. Available at: http://lib.post.ca.gov/Publications/Cardio.pdf. Accessed July 3, 2018.
  22. Maron BJ, Zipes Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities – general considerations. J Am Coll Cardiol. 2005;45(8):1313-21. Available at: http://content.onlinejacc.org/cgi/content/full/45/8/1318. Accessed July 3, 2018.
  23. Pelliccia A, Zipes DP, Maron BJ. Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations revisited: a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol. 2008;52(24):1990-6. Available at: sciencedirect.com/science/article/pii/S0735109708031884. Accessed July 3, 2018.
  24. Lauer M, Froelicher ES, Williams M, Kligfield Exercise testing in asymptomatic adults: a statement for professionals from the American Heart Association Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation. 2005;112(5):771-6.
  25. Fletcher GF, Ades PA, Klingfield P, et al. Exercise standards for testing and training: a statement from the American Heart Association. Circulation. 2013;128:873-934.
  26. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 Guideline Update for Exercise Testing: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). 2002. Available at: http://www.cardiology.org/recentpapers/exercisegl02.pdf. Accessed July 3, 2018.
  27. Thompson PD, Myerburg RJ, Levine BD, et al.; on behalf of the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and the American College of Cardiology. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 8: coronary artery disease: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015;66:2406-11.
  28. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guidelines for assessment of cardiovascular risk in symptomatic adults. J Am Coll Cardiol. 2010;56(25):e50-103.
  29. O’Rourke RA, Brundage BJ, Froelicher VF, et al. American College of Cardiology/American Heart Association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol. 2000;36(1):326-40. Available at: http://content.onlinejacc.org/cgi/content/full/36/1/326. Accessed July 3, 2018.
  30. Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. 2004;291(2):210-21.
  31. Mark DB, Berman DS, Budoff MJ, et al. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;121:2509-43.
  32. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):3097-137.
  33. National Fire Protection Association. 1582 Standard on Comprehensive Occupational Medical Program for Fire Departments. Quincy: Mass; 2007.
  34. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240-e319.
  35. Takagi Y, Yasuda S, Tsunoda R, et al. Clinical characteristics and long-term prognosis of vasospastic angina patients who survived out-of-hospital cardiac arrest: multicenter registry study of the Japanese Coronary Spasm Association. Circ Arrhythm Electrophysiol. 2011;4:295-302.
  36. Ong P, Athanasiadis A, Borgulya G, et al. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries: the ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol. 2012;59:655-62.
  37. Michelis KC, Olin JW, Kadian-Dodov D, et al. Coronary artery manifestations of fibromuscular dysplasia. J Am Coll Cardiol. 2014;64:1033-46.
  38. Kalaga RV, Malik A, Thompson PD. Exercise related spontaneous coronary artery dissection: case report and literature review. Med Sci Sports Exerc. 2007;39:1218-20.
  39. Baggish AL, Thompson PD. The athlete’s heart 2007: diseases of the coronary circulation. Cardiol Clin. 2007;25:431-40.
  40. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease: a 10- to21-year follow-up study of 594 patients. 1996;94:1379-85.
  41. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997;131:888-93.
  42. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association [published correction in Pediatrics. 2005;115:1118]. 2004;114:1708-33.
  43. Rowe J. Cardiovascular Evaluation of Army Civilian Police and Security Guards. Internal guidance memorandum MEDCOM Regional Medical Commands, Department of the Army. Undated.
  44. FMCSA Evidence Report. Cardiovascular Disease and Commercial Motor Vehicle Driver Safety. FMCSA (Federal Motor Carrier Safety Administration). 2007, p. 38. Available at: https://rosap.ntl.bts.gov/view/dot/16462. Accessed July 3, 2018.